Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Completed · Phase 2 · Has a placebo group

Conditions studied: Meningococcal Disease

In brief

The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.

Key facts

Study ID

NCT00297817

Run by

Novartis Vaccines

People needed

203

Starts

2006-02-01

Expected to finish

2007-04-01

Last updated by the study team

2016-12-01

Who can join

Age: 11 and older, up to 18. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy Adolescents between and including 11-18 years of age, who provide written informed consent.

You may not qualify if…

• Previous or suspected disease caused by N. meningitidis; or previous immunization with a serogroup B meningococcal vaccine; Any acute, chronic or progressive disease.

Where it is running

• Study site — Encinitas, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — St Louis, Missouri, United States
• Study site — Cleveland, Ohio, United States
• Study site — Galveston, Texas, United States
• Study site — Layton, Utah, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.